ViroGates has completed the development and regulatory approval of its first suPARnostic\u00ae TurbiLatex product, based on the turbidimetric technology. The suPARnostic\u00ae TurbiLatex product has initially been developed and approved for the\u00a0Roche Diagnostics cobas C 111 analyzer. Roche Diagnostics is the market leader in the clinical chemistry area in the hospital markets in Europe and offers integrated diagnostic solutions on its cobas platforms. The launch of the cobas C 111 application is the\u00a0first step in providing products for the Roche Diagnostics platform. Next step is to validate the suPARnostic\u00ae TurbiLatex on the higher throughput instruments such as the\u00a0cobas c 500 and c 700 series\u00a0that are most commonly used in diagnostic laboratories. The suPARnostic\u00ae\u00a0 Turbilatex product enables automatic handling of blood samples at central laboratories,\u00a0and allows the medical professionals to obtain results in exactly the same manner that most other blood parameters are reported. This means, that doctors will be able to\u00a0obtain suPAR measurements at the same time as they receive most other diagnostic data\u00a0thereby facilitating efficient decision making. The TurbiLatex product is based on\u00a0a technology called turbidimetry\u00a0that measures the loss of intensity of transmitted light due to the scattering effect of particles suspended in the blood sample. The principle of measuring blood samples by using turbidimetry is very important in relation to immunoassays, as it is the basis for almost all central laboratory clinical chemistry instrument platforms in hospitals.